Clinical trial
Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for…
NCT00257114 · Millennium Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00257114 |
|---|---|
| Title | Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability |
| Official title | Evaluation of VELCADE (Botezomib) for Injection Employed as Re-Treatment for Efficacy, Safety, and Tolerability |
| Lead sponsor | Millennium Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | bortezomib |
| Primary completion | Mar 1, 2007 |
| First posted | Nov 22, 2005 |
| Last update posted | Feb 11, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: